As example, in metastatic melanoma patients, it has been shown that expression levels of PD-L1 on circulating exosomes can be modified during treatment with ICIs and those changes might be related to the development of therapy resistance and the type of responses obtained [48]. The gene discussed is CD274; the disease is metastatic melanoma.